Financial
FY2025 revenue $6.16bn (+6.1%); operating margin 12.9%; net income $625.0m.
Net debt $2.76bn including leases.
HQ United Kingdom · Europe
Directory listing. Financial health and risk summaries come from public sources only (see below); products have not been catalogued yet. Source: HSH editorial list from public company information, November 2026 — awaiting verification.
FY2025 revenue $6.16bn (+6.1%); operating margin 12.9%; net income $625.0m.
Net debt $2.76bn including leases.
Source: official results release · Year ended 2025-12-31 · Band from the latest full-year operating margin in official results: 10% or more Strong, 0–10% Fair, below 0 Weak. Where operating profit is not published, the stated alternative margin is used. Not assessed means no usable public figures.
| Year | Revenue | Growth | Operating profit | Net income | Covers |
|---|---|---|---|---|---|
| FY2025 | US$6.2bn | +6.1% | US$794m | US$625m | Smith & Nephew |
Products not yet catalogued.
FY2025 revenue $6.16bn (+6.1%); operating margin 12.9%; net income $625.0m.
Net debt $2.76bn including leases.
Nov 2026: Smith & Nephew cut its 2026 guidance, citing weaker US Orthopaedics growth, and said earlier talks with Johnson & Johnson on a possible deal involving its Orthopaedics division had ended; it is still exploring options for that division.
Feb 2026: the 0apt ransomware group claimed to have taken data from Smith & Nephew (UK), according to a threat-intelligence site; the claim is unverified and no company confirmation was found. NHS DSPT status not yet checked.
Sep 2026: FDA Class 2 recall of an EVOS proximal tibia plate for incorrect labelling. Mar 2026: Class 2 recall of a lot of TRIGEN humeral nails made without some distal holes, which the notice says could lead to revision surgery.
No notable NHS contract awards, terminations or customer disputes involving Smith & Nephew found in HSH's search of the last 24 months.
No competitors linked yet.